Circassia Pharmaceuticals Plc (CIR):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Circassia Pharmaceuticals Plc (CIR) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7065
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease. The company had several inhaled medicines in pipeline intended for the treatment chronic obstructive pulmonary disease (COPD), which include single and combination dose products. The company offers its products to COPD and asthma specialists in the US, the UK, Germany and other countries through its network of partners. Circassia is headquartered in Oxford, England, the UK.

Circassia Pharmaceuticals Plc (CIR) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Circassia Pharmaceuticals Plc, Medical Equipment, Deal Details 10
Venture Financing 10
Prosonix Raises Additional US$9 Million In Series B Financing Round 10
Partnerships 12
Circassia Pharma Enters into Licensing Agreement with NanoPass Technologies 12
Aerocrine Enters Into Licensing Agreement With Medisoft 13
Aerocrine Enters Into Distribution Agreement With Shanghai Pharma For Niox Mino And Test Kits 14
Aerocrine Enters Into Distribution Agreement With Stallergenes For Niox Mino 15
Centre of Excellence for Prevention of Organ Failure Enters Into Co-Development Agreement With Adiga Life Sciences For Proteomic And Genomic Biomarkers 16
Equity Offering 17
Aerocrine Raises USD60 Million in Rights Offering of Shares 17
Aerocrine Completes Private Placement Of Shares For US$15 Million 19
Aerocrine Completes Rights Offering Of Common Stock For US$36 Million 20
Acquisition 21
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 21
Circassia Pharmaceuticals Acquires Aerocrine 22
Circassia Pharma Acquires Prosonix for USD157.6 Million 24
Circassia Pharmaceuticals Plc – Key Competitors 26
Circassia Pharmaceuticals Plc – Key Employees 27
Circassia Pharmaceuticals Plc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Sep 27, 2018: Circassia – Interim results for the six months ended 30 June 2018 29
Sep 27, 2018: Circassia Pharmaceuticals interim results for the six months ended 30 june 2018 33
Apr 24, 2018: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2017 47
Sep 27, 2017: Circassia Pharmaceuticals: Interim Results for the Six Months Ended 30 June 2017 48
Apr 25, 2017: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2016 49
Corporate Communications 50
Feb 13, 2018: Circassia Announces Changes to its Board of Directors 50
Apr 25, 2017: Circassia Announces Non-Executive Director Retirements 51
Government and Public Interest 52
Nov 29, 2017: Circassia Welcomes New NICE Guidelines Recommending Use of FeNO Testing in Asthma Diagnosis 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Circassia Pharmaceuticals Plc, Medical Equipment, Key Facts, 2017 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Deals By Market, 2012 to YTD 2018 8
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Prosonix Raises Additional US$9 Million In Series B Financing Round 10
Circassia Pharma Enters into Licensing Agreement with NanoPass Technologies 12
Aerocrine Enters Into Licensing Agreement With Medisoft 13
Aerocrine Enters Into Distribution Agreement With Shanghai Pharma For Niox Mino And Test Kits 14
Aerocrine Enters Into Distribution Agreement With Stallergenes For Niox Mino 15
Centre of Excellence for Prevention of Organ Failure Enters Into Co-Development Agreement With Adiga Life Sciences For Proteomic And Genomic Biomarkers 16
Aerocrine Raises USD60 Million in Rights Offering of Shares 17
Aerocrine Completes Private Placement Of Shares For US$15 Million 19
Aerocrine Completes Rights Offering Of Common Stock For US$36 Million 20
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 21
Circassia Pharmaceuticals Acquires Aerocrine 22
Circassia Pharma Acquires Prosonix for USD157.6 Million 24
Circassia Pharmaceuticals Plc, Key Competitors 26
Circassia Pharmaceuticals Plc, Key Employees 27
Circassia Pharmaceuticals Plc, Subsidiaries 28

List of Figures
Circassia Pharmaceuticals Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Circassia Pharmaceuticals Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Circassia Pharmaceuticals Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Circassia Pharmaceuticals Plc (CIR):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • V.F. Corporation (VFC):企業の財務・戦略的SWOT分析
    V.F. Corporation (VFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Avidity Biosciences LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Avidity Biosciences LLC (Avidity Biosciences), formerly Avidity NanoMedicines LLC is a biotech company that develops antibody oligonucleotide conjugates (AOCs). The company’s proprietary platform technology has enhanced pharmacokinetic and biodistribution properties that improves the deliver …
  • Alphabet Inc:企業の戦略・SWOT・財務情報
    Alphabet Inc - Strategy, SWOT and Corporate Finance Report Summary Alphabet Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Otonomy Inc (OTIC):製薬・医療:M&Aディール及び事業提携情報
    Summary Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company’s Otiprio is the US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses Otividex for …
  • Green Dot Corporation:企業の戦略・SWOT・財務分析
    Green Dot Corporation - Strategy, SWOT and Corporate Finance Report Summary Green Dot Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Alacer Gold Corp:企業の戦略・SWOT・財務情報
    Alacer Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Alacer Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Lockheed Martin Missiles and Fire Control:企業の戦略・SWOT・財務情報
    Lockheed Martin Missiles and Fire Control - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Missiles and Fire Control - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • ADAMA Agricultural Solutions Ltd.:企業の戦略的SWOT分析
    ADAMA Agricultural Solutions Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Shopping Centres Australasia Property Group RE Limited:企業の戦略・SWOT・財務情報
    Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report Summary Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • AbbVie Inc (ABBV)-製薬・医療分野:企業M&A・提携分析
    Summary AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that carries out the research, development, manufacture and commercialization of advanced therapies to treat complex and serious diseases. The company focuses on providing drugs in immunology, cancer, neuroscience and virology …
  • Emergent BioSolutions Inc (EBS):医療機器:M&Aディール及び事業提携情報
    Summary Emergent BioSolutions Inc (Emergent) is a life sciences company. It focuses on protecting and enhancing life by providing specialized products to governments and healthcare providers. The company develops specialty products targeting public health threats and emerging infectious diseases. It …
  • Sensorion SA (ALSEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Sensorion SA (Sensorion) is a biopharmaceutical company that develops therapies. The company provides treatments for vestibular and cochlear pathologies. It develops drug candidates through its technology platform for the treatment of various therapeutic areas including vestibular neuritis, …
  • Ameren Corp (AEE):企業の財務・戦略的SWOT分析
    Ameren Corp (AEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • PGNiG SA (PGN):企業の財務・戦略的SWOT分析
    PGNiG SA (PGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Anadarko Petroleum Corp (APC):石油・ガス:M&Aディール及び事業提携情報
    Summary Anadarko Petroleum Corp (Anadarko) is an independent upstream oil and gas company, which carries out exploration, development, production, and marketing of natural gas, crude oil, condensate, and natural gas liquids (NGLs) from its assets. It also involves in gathering, processing, treating, …
  • Caris Life Sciences Inc:企業の製品パイプライン分析
    Summary Caris Life Sciences Inc (Caris Life) is a biotechnology company. The company’s molecular scientific offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make personalized treatment decisions. Its ADAPT biotargeting system, is a plat …
  • Apogenix AG-製薬・医療分野:企業M&A・提携分析
    Summary Apogenix AG (Apogenix) is a biopharmaceutical company, developing immuno-oncology medicines for the treatment of cancer and other malignant diseases. Its pipeline drug candidates under clinical development include Asunercept (APG101), a CD95 ligand inhibitor, for the treatment of glioblastom …
  • HRG Group, Inc. (HRG)-石油・ガス分野:企業M&A・提携分析
    Summary HRG Group, Inc. (HRG), formerly, Harbinger Group Inc., is a diversified investment holding company, with interests in various businesses such as branded consumer products, which include consumer batteries, residential locksets, faucets, shaving and grooming products, personal care products, …
  • KAMCO Investment Company K.S.C.P. (KAMCO):企業の財務・戦略的SWOT分析
    KAMCO Investment Company K.S.C.P. (KAMCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • CellSeed Inc (7776):企業の財務・戦略的SWOT分析
    Summary CellSeed Inc (CellSeed) is a developer of regenerative medicine. The company’s products include epithelial cell sheet for corneal regeneration, regenerated cardiac patch, epithelial cell sheet for esophageal regeneration, cell sheet for periodontal tissue regeneration and regenerated cartila …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆